INNOVATE.

VALIDATE.

SOLVE.

At-Home Vertigo Study
Enrolling Soon.

INNOVATE.

VALIDATE.

SOLVE.

At-Home Vertigo Study
Enrolling Soon.

Lightbulb Icon

Groundbreaking Technology

Our patented technology utilizes non-invasive Vestibular Resonance Therapy (nVRT) to impact the vestibular system.

Medical Icon

First Vertigo Wearable

We are developing a noninvasive and easy-to-use wearable solution for chronic vertigo, which is suffered by over 11 million Americans.

Headband Icon

Non-Invasive, Non-Pharmacological

The compact, headworn wearable device requires no surgery, advanced patient calibration, or complex fittings.

Compact Icon

Designed To Be Safe

Through development and clinical studies, our device has been used on over 600 subjects, with zero reportable serious device-related adverse events.

At-home Vertigo Study

Enrollment will be limited and there will be no cost to you. The OtoBand is a new investigational device that is being tested to see if it reduces the symptoms of vertigo. 

  • Telehealth study
  • Non-invasive device
  • Participant is compensated

Working With

Ford Logo
U.S. Air Force Logo
Land Rover Logo
Audi Logo

Latest News

Otolith Labs Rounds Out Executive Team with Hiring of Chief Clinical Officer

Otolith Labs Rounds Out Executive Team with Hiring of Chief Clinical Officer

Kevin Franck, PhD, MBA appointed as Otolith Labs’ Chief Clinical Officer.

Otolith Expands Leadership Team with CCO and New Board Member

Otolith Expands Leadership Team with CCO and New Board Member

Otolith appointed Dan Wagner as Chief Commercial Officer and Raphael Michel to Otolith’s Board of Directors.

Mark Cuban-Backed Otolith Labs Just Raised Another $20M

Mark Cuban-Backed Otolith Labs Just Raised Another $20M

Technical.ly interviews Otolith’s CEO Sam Owen about the pressing need for a new treatment option for chronic vertigo.

Otolith Receives FDA Breakthrough Device Designation

Otolith Receives FDA Breakthrough Device Designation

Otolith Labs announces closing of $3.3 Million in seed funding, as well as receiving “Breakthrough Device” Designation from FDA.

200 Massachusetts Ave NW, Floor 7, Washington, DC 20001

© 2024 Otolith Labs, Inc.